お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:抗肥満薬の世界市場 - 予測:2020年~2030年
市場調査レポート
商品コード
933206

抗肥満薬の世界市場 - 予測:2020年~2030年

Global Anti-Obesity Drugs Market Forecast 2020-2030

出版日: | 発行: Visiongain Ltd | ページ情報: 英文 285 Pages | 納期: 即日から翌営業日

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=158.36円

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

抗肥満薬の世界市場 - 予測:2020年~2030年
出版日: 2020年02月27日
発行: Visiongain Ltd
ページ情報: 英文 285 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗肥満薬市場は、2019年に19億米ドルに達し、予測期間中の前半のCAGRで32%の成長が予測されています。2019年、イノベーター医薬品のサブマーケットが、世界の抗肥満薬市場の75%を占めています。将来のビジネスチャンスを活用するために、市場に関する詳細な考察を提供します。市場に影響を与える主な要因や課題も提供します。

当レポートでは、世界の抗肥満薬市場について調査分析し、市場概要、市場力学、市場予測、主要企業などについて、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 肥満のイントロダクション

  • 肥満とは
  • 肥満の原因と危険因子
  • 肥満測定
  • 肥満の疫学
  • 人道的・経済的負担
  • 肥満:予防と治療

第3章 世界の抗肥満薬市場のイントロダクション

  • 市場構造
  • 市場の定義と範囲
  • 分類:作用機序別
  • 分類:イノベーター/ジェネリック医薬品別
  • 分類:処方/OTC医薬品別
  • 分類:治療期間別

第4章 世界の抗肥満薬市場

  • 世界の抗肥満薬市場
  • 世界の抗肥満薬市場の予測
  • 世界の抗肥満薬市場:作用機序別
  • 世界の抗肥満薬市場:イノベーター/ジェネリック医薬品別
  • 世界の抗肥満薬市場:処方/OTC医薬品別
  • 世界の抗肥満薬市場:治療期間別
  • 世界の抗肥満薬市場全体の市場促進要因・抑制要因・動向

第5章 主要な抗肥満薬

  • 抗肥満薬のスナップショット
  • イノベーター医薬品
    • Saxenda
    • Contrave/Mysimba
    • Belviq
    • Qysmia
    • Xenical and Alli
    • Cametor/Oblean
    • Lomaira
  • ジェネリック医薬品
    • Orlistat
    • Sibutramine
    • Adipex
    • Phentermine

第6章 主要国市場の予測

  • 世界の抗肥満薬市場の地理的内訳
  • 世界の抗肥満薬市場の地域別予測
  • 米国
  • 日本
  • EU5ヶ国
  • BRIC諸国

第7章 肥満治療の研究開発

  • パイプライン医薬品の新しい作用機序
  • 有効なパイプライン分子
  • 将来有望なパイプライン分子

第8章 価格と償還の概要

  • 米国
  • EU
  • 保険者の見通し

第9章 世界の抗肥満薬市場の定性分析

  • SWOT分析
  • 市場動向

第10章 世界の抗肥満薬市場における主要企業

  • Novo Nordisk
  • Currax Pharmaceuticals LLC
  • エーザイ
  • F. Hoffmann-La Roche Ltd.
  • Vivus
  • Teva
  • GlaxoSmithKline (GSK)
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • AstraZeneca
  • Saniona
  • Hanmi Pharmaceutical
  • SCOHIA PHARMA, Inc.
  • Sinil Pharmaceutical Co., Ltd
  • ERX Pharmaceuticals
  • CohBar, Inc.
  • Carmot Therapeutics, Inc.
  • LNC Therapeutics
  • Gelesis

第11章 結論

図表

List of Table

  • Table 2.1: WHO BMI Cut Off Points
  • Table 2.2 Classification of Overweight and Obesity by BMI, Waist Circumference, and Associated Disease Risk
  • Table 2.3 Prevalence of obesity among adults (both sexes 18+), BMI ≥ 30, age-standardized Estimates by WHO region
  • Table 2.4 Prevalence of obesity (Male 18+), BMI ≥ 30, age-standardized Estimates by WHO region
  • Table 2.5 Prevalence of obesity (Female 18+), BMI ≥ 30, age-standardized Estimates by WHO region
  • Table 2.6 Forecast of Obesity Prevalence in Major Markets (US, EU5, BRIC, and Japan), Both Sexes, aged >18 years, 2019-2030, million, CAGR% (2019-2030)
  • Table 3.1 Mechanism of Action of Innovator Drugs for the treatment of Obesity
  • Table 3.2 List of Innovator Drugs for the treatment of Obesity
  • Table 3.2 List of Prescription Drugs for the treatment of Obesity
  • Table 3.3 Long-term Prescription Drugs for the treatment of Obesity
  • Table 4.1 Global Anti-obesity Drugs Market by Markets: Revenue ($m), and Market Share (%), 2019
  • Table 4.2 Global Anti-obesity Drugs Market Forecast 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.3 Global Anti-obesity Drugs Market Segmentation by Mechanism of Action 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.4 Global Anti-obesity Drugs Market by Mechanism of Action 2020-2030: AGR (%)
  • Table 4.5 Global Anti-obesity Incretin mimetics/GLP-1 Agonist Drugs Market 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.6 List of Active GLP-1 agonists in Clinical Pipeline
  • Table 4.7 Global Anti-obesity Lipase Inhibitor Drugs Market 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.8 List of Active SNDRI agonists in Clinical Pipeline
  • Table 4.9 Global Anti-obesity Serotonin-norepinephrine-Dopamine Reuptake Inhibitor Drugs Market 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.10 Global Anti-obesity Serotonin Receptor Agonist Drugs Market 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.11 Global Anti-obesity Sympathomimetic-GABA Receptor Agonist Drugs Market 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.12 Global Anti-obesity Sympathomimetic Drugs Market 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.13 Global Anti-obesity Other Drugs Market 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.14 Global Anti-obesity Drugs Market by Mechanism of Action 2020-2030: Market Share (%)
  • Table 4.15 Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.16 Global Anti-obesity Drugs Market Segmentation by Innovator Drugs and Generics 2020-2030: AGR (%)
  • Table 4.17 Global Anti-obesity Innovator Drugs Market 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.18 Global Anti-obesity Generic Drugs Market 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.19 Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2020-2030: Market Share (%)
  • Table 4.20 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.21 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2020-2030: AGR (%)
  • Table 4.22 Global Anti-obesity Prescription Drugs Market 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.20 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.24 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Market Share (%)
  • Table 4.25 Global Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.26 Global Anti-obesity Drugs Market by Duration of Therapy 2020-2030: AGR (%)
  • Table 4.27 Global Anti-obesity Short-term Drugs Market 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.28 Global Anti-obesity Long-term Drugs Market 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.29 Global Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Market Share (%)
  • Table 5.1 Saxenda Drug Profile
  • Table 5.2 Saxenda Sales Forecast 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.3 Contrave Drug Profile
  • Table 5.4 Contrave Sales Forecast 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.5 Belviq Drug Profile
  • Table 5.6 Belviq Sales Forecast 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.7 Qysmia Drug Profile
  • Table 5.8 Qysmia Sales Forecast 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 5.9 Alli Sales Forecast 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.1 Global Anti-obesity Drugs Market by Region: Revenue ($m), and Market Share (%), 2019
  • Table 6.2 Global Anti-obesity Drugs Market by Country: Revenue ($m), and Market Share (%), 2019
  • Table 6.3 Global Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 6.4 Global Anti-obesity Drugs Market by Region: AGR 2020-2030 (%)
  • Table 6.5 Global Anti-obesity Drugs Market by Region: Market Share (%), 2019-2030
  • Table 6.6 US Anti-obesity Drugs Market Forecast 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.7 U.S. Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.8 U.S. Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.9 US Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.10 US Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.11 Japan Anti-obesity Drugs Market Forecast 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.12 Japan Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.13 Japan Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.14 Japan Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.15 Japan Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.16 EU5 Anti-obesity Drugs Market by Region: Market Size ($m) and Share (%), 2019
  • Table 6.17 EU5 Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 6.18 EU5 Anti-obesity Drugs Market by Region: Market Share Forecast 2019-2030 (%)
  • Table 6.19 EU5 Anti-obesity Drugs Market Forecast by Region: AGR (%) 2019-2030
  • Table 6.20 UK Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 6.21 UK Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.22 UK Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.23 UK Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.24 UK Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.25 Germany Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 6.26 Germany Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.27 Germany Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.28 Germany Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.29 Germany Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.30 France Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 6.31 France Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.32 France Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.33 France Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.34 France Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.35 Italy Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 6.36 Italy Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.37 Italy Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.38 Italy Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.39 Italy Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.40 Spain Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 6.41 Spain Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.42 Spain Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.43 Spain Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.44 Spain Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.45 Anti-obesity Drugs Market in the BRIC Region: Market Size ($m) & Share 2019 (%)
  • Table 6.46 BRIC Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 6.47 China Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 6.48 China Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.49 China Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.50 China Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.51 China Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.52 India Anti-obesity Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 6.53 India Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.54 India Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.55 India Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.56 India Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.57 Brazil Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 6.58 Brazil Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.59 Brazil Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.60 Brazil Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.61 Brazil Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.62 Russia Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2030
  • Table 6.63 Russia Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.64 Russia Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.65 Russia Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.66 Russia Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%), CAGR (%)
  • Table 7.1 Active Pipeline Molecules under Development for Treating Obesity
  • Table 9.1 The number of operations performed in all responding nations of the world
  • Table 9.2 Number of undernourished individuals worldwide, 2005-2017
  • Table 9.3 Prevalence of excess bodyweight in school-age children, 2010-2013
  • Table 9.4 Common Ingredients in Weight-Loss Dietary Supplements
  • Table 10.1: Innovator Drugs' Originator-Licensee Information
  • Table 10.2 Novo Nordisk A/S: Overview
  • Table 10.3 Novo Nordisk: Patent Status for Marketed Products
  • Table 10.3 Novo Nordisk: Pipeline Overview (Obesity)
  • Table 10.4 Currax Pharmaceuticals LLC: Overview
  • Table 10.5 Eisai Co., Ltd.: Overview
  • Table 10.6 Roche: Overview
  • Table 10.7 Vivus: Overview
  • Table 10.8 Teva: Overview
  • Table 10.9 GSK: Overview
  • Table 10.10 Pfizer Inc.: Overview
  • Table 10.11 Rhythm Pharmaceuticals, Inc.: Overview
  • Table 10.12 Product Pipeline: Setmelanotide
  • Table 10.13 AstraZeneca: Overview
  • Table 10.14 Saniona: Overview
  • Table 10.15 Hanmi Pharmaceutical: Overview
  • Table 10.16 Hanmi Pharmaceutical: Pipeline
  • Table 10.17 SCOHIA PHARMA, Inc.: Overview
  • Table 10.18 SCOHIA PHARMA, Inc.: Pipeline
  • Table 10.19 Sinil Pharmaceutical Co., Ltd: Overview
  • Table 10.20 ERX Pharmaceuticals: Overview
  • Table 10.21 CohBar, Inc.: Overview
  • Table 10.22 Carmot Therapeutics, Inc.: Overview
  • Table 10.23 Carmot Therapeutics, Inc.: Pipeline
  • Table 10.24 LNC Therapeutics: Overview
  • Table 10.25 Gelesis: Overview
  • Table 10.26 Gelesis: Pipeline

List of Figure

  • Figure 2.1 Percentage of adults with obesity in the United States by State, 2018
  • Figure 2.2 Prevalence of Obesity in OECD 32 Countries - population aged 15 years and over, 2013 or nearest year
  • Figure 2.3 Prevalence of Obesity in G7 and BRIC Countries - population aged 15 years and over, 2012 or nearest year, men, women, both sexes
  • Figure 2.4 Age-Standardized Obesity Prevalence Rate in Major Markets - Population aged 15 years and over, 1972-2016
  • Figure 2.5 Deaths due to Obesity in G7 and BRIC Nation: Absolute Number (000's), 2015
  • Figure 2.6 DALY's due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015
  • Figure 2.7 YLD's due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015
  • Figure 2.8 YLL's due to Obesity in G7 and BRIC Nation: Absolute Number (000's), 2015
  • Figure 4.1 Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2019
  • Figure 4.2 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2019
  • Figure 4.3 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2019
  • Figure 4.4 Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2019
  • Figure 4.5 Global Anti-obesity Drugs Market Forecast 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.6 Global Anti-obesity Drugs Market by Mechanism of Action 2019, Revenue ($m)
  • Figure 4.7 Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2019
  • Figure 4.8 Global Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Revenue ($m), Global AGR (%)
  • Figure 4.9 Global Anti-obesity Drugs Market by Mechanism of Action 2020 and 2030: Revenue ($m), CAGR (%) 2020-2030
  • Figure 4.10 Global Anti-obesity Drugs Market by Mechanism of Action 2020-2030: AGR (%)
  • Figure 4.11 Global Anti-obesity Incretin mimetics/GLP-1 Agonist Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.12 Global Anti-obesity Lipase Inhibitor Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.13 Global Anti-obesity Serotonin-norepinephrine-Dopamine Reuptake Inhibitor Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.14 Global Anti-obesity Serotonin Receptor Agonist Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.15 Global Anti-obesity Sympathomimetic-GABA Receptor Agonist Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.16 Global Anti-obesity Sympathomimetic Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.17 Global Anti-obesity Other Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.18 Global Anti-obesity Drugs Market by Mechanism of Action 2019-2030: Market Share (%)
  • Figure 4.19 Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2025
  • Figure 4.20 Global Anti-obesity Drugs Market by Mechanism of Action: Market Share (%), 2030
  • Figure 4.21 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Revenue ($m), 2019
  • Figure 4.22 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Revenue ($m), 2019
  • Figure 4.23 Global Anti-obesity Drugs Market Segmentation by Innovator Drugs and Generics 2019-2030: Revenue ($m), Global AGR (%)
  • Figure 4.24 Global Anti-obesity Drugs Market Segmentation by Innovator Drugs and Generics: Revenue 2020 and 2030 ($m), CAGR 2020-2030 (%)
  • Figure 4.25 Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: AGR (%)
  • Figure 4.26 Global Anti-obesity Innovator Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.27 Global Anti-obesity Generic Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.28 Global Anti-obesity Drugs Market by Innovator Drugs and Generics 2019-2030: Market Share (%)
  • Figure 4.29 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2020
  • Figure 4.30 Global Anti-obesity Drugs Market by Innovator Drugs and Generics: Market Share (%), 2030
  • Figure 4.31 Global Anti-obesity Drugs Market by Prescription and OTC Drugs, Revenue 2019 ($m)
  • Figure 4.32 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2019
  • Figure 4.33 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Revenue ($m), Global AGR (%)
  • Figure 4.34 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Revenue 2020 and 2030 ($m), CAGR 2020-2030(%)
  • Figure 4.35 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2020-2030: AGR (%)
  • Figure 4.36 Global Anti-obesity Prescription Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.37 Global Anti-obesity OTC Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.38 Global Anti-obesity Drugs Market by Prescription and OTC Drugs 2019-2030: Market Share (%)
  • Figure 4.39 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2019
  • Figure 4.40 Global Anti-obesity Drugs Market by Prescription and OTC Drugs: Market Share (%), 2030
  • Figure 4.41 Global Anti-obesity Drugs Market by Duration of Therapy: Revenue ($m), 2019
  • Figure 4.42 Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2019
  • Figure 4.43 Global Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.44 Global Anti-obesity Drugs Market by Duration of Therapy: Revenue 2020 and 2030 ($m), CAGR 2020-2030 (%)
  • Figure 4.45 Global Anti-obesity Drugs Market by Duration of Therapy 2019-2030: AGR (%)
  • Figure 4.46 Global Anti-obesity Short-term Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.47 Global Anti-obesity Long-term Drugs Market 2019-2030: Revenue ($m), AGR (%)
  • Figure 4.48 Global Anti-obesity Drugs Market by Duration of Therapy 2019-2030: Market Share (%)
  • Figure 4.49 Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2019
  • Figure 4.50 Global Anti-obesity Drugs Market by Duration of Therapy: Market Share (%), 2030
  • Figure 4.51 Global Anti-obesity Drugs Market: Drivers and Restraints
  • Figure 4.52 Trends in Global Anti-obesity Drugs Market
  • Figure 5.1 Leading Anti-obesity Drug Sales, Revenue ($m), 2018
  • Figure 5.2 Leading Anti-obesity Drug Sales, Market Share (%), 2018
  • Figure 5.3 Anti-obesity Drugs Sales Forecast, Market Share (%), 2030
  • Figure 5.4 Leading Anti-obesity Drugs: Historical Revenue ($m), 2012-2018
  • Figure 5.5 Global Anti-obesity Innovator Drugs by Individual Drug: Market Share (%), 2018
  • Figure 5.6 Global Anti-obesity Innovator Drugs by Individual Drug: Market Share (%), 2030
  • Figure 5.7 Saxenda Global Sales: Revenue ($million), 2015-2018
  • Figure 5.8 Saxenda Sales Forecast 2019-2030: Revenue ($m), AGR (%)
  • Figure 5.9 Saxenda Sales Forecast 2019-2030: Revenue ($m), AGR (%)
  • Figure 5.10 Contrave Global Sales: Revenue ($million), 2014-2016
  • Figure 5.11 Contrave Sales Forecast 2019-2030: Revenue ($m), AGR (%)
  • Figure 5.12 Contrave Sales by Geography: Market Share (%), 2018
  • Figure 5.13 Belviq Global Sales: Revenue ($million), 2013-2018
  • Figure 5.14 Belviq Sales Forecast 2019-2030: Revenue ($million), AGR (%)
  • Figure 5.15 Belviq Sales by Geography: Market Share (%), 2018
  • Figure 5.16 Qysmia Global Sales: Revenue ($m), 2013-2018
  • Figure 5.17 Qysmia Sales Forecast 2019-2030: Revenue ($m), AGR (%)
  • Figure 5.18 Qysmia Sales by Geography: Market Share (%), 2018
  • Figure 5.19 Xenical Global Sales: Revenue ($million), 2013-2018
  • Figure 5.20 Alli Global Sales: Revenue ($million), 2013-2018
  • Figure 5.21 Xenical Sales by Geography: Market Share (%), 2018
  • Figure 5.22 Alli Sales by Geography: Market Share (%), 2018
  • Figure 5.23 Alli Sales Forecast 2019-2030: Revenue ($m), AGR (%)
  • Figure 5.24 Global Anti-obesity Generics Market by Individual Compound: Market Share (%), 2018
  • Figure 5.25 Orlistat Global Sales: Revenue ($m), 2013-2018
  • Figure 5.26 Sibutramine Global Sales: Revenue ($m), 2013-2018
  • Figure 5.27 Adipex Global Sales: Revenue ($m), 2013-2018
  • Figure 5.28 Phentermine Global Sales: Revenue ($m), 2013-2018
  • Figure 6.1 Global Anti-obesity Drugs Market Segmentation by Region/Country
  • Figure 6.2 Global Anti-obesity Drugs Market by Region: Revenue ($m), CAGR%, 2020, 2025 & 2030
  • Figure 6.3 Global Anti-obesity Drugs Market by Region: Market Share (%), 2020
  • Figure 6.4 Global Anti-obesity Drugs Market by Country: Revenue ($m), 2019
  • Figure 6.5 Global Anti-obesity Drugs Market by Country: Market Share (%), 2030
  • Figure 6.6 Global Anti-obesity Drugs Market Forecast by Region: Revenue ($m), Global AGR (%), 2019-2030
  • Figure 6.7 Global Anti-obesity Drugs Market Forecast by Region 2020, 2025, 2030: Revenue ($m), CAGR 2020-2030 (%)
  • Figure 6.8 Global Anti-obesity Drugs Market by Region: AGR 2020-2030 (%)
  • Figure 6.9 Global Anti-obesity Drugs Market by Region: Market Share (%), 2019-2030
  • Figure 6.10 Global Anti-obesity Drugs Market by Region: Market Share (%), 2020
  • Figure 6.11 Global Anti-obesity Drugs Market by Region: Market Share (%), 2025
  • Figure 6.12 Global Anti-obesity Drugs Market by Region: Market Share (%), 2030
  • Figure 6.13 US Anti-obesity Drugs Market by Mechanism of Action: Market Share %, 2019
  • Figure 6.14 US Anti-obesity Drugs Market Forecast 2019-2030: Revenue ($m), AGR (%)
  • Figure 6.15 Japan Anti-obesity Drugs Market Forecast 2019-2030: Revenue ($m), AGR (%)
  • Figure 6.16 EU5 Anti-obesity Drugs Market by Region: Global Market Share (%), 2019
  • Figure 6.17 EU5 Anti-obesity Drugs Market by Region: Market Share (%), 2019
  • Figure 6.18 EU5 Anti-obesity Drugs Market Forecast by Region 2019-2030: Revenue ($m), AGR (%)
  • Figure 6.19 EU5 Anti-obesity Drugs Market by Region 2020 and 2030: Revenue ($m), CAGR 2019-2030 (%)
  • Figure 6.20 EU5 Anti-obesity Drugs Market by Region: Market Share Forecast 2019-2030 (%)
  • Figure 6.23 EU5 Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2030
  • Figure 6.25 UK Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2030
  • Figure 6.26 Germany Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2030
  • Figure 6.27 France Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2030
  • Figure 6.28 Italy Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2030
  • Figure 6.29 Spain Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2030
  • Figure 6.30 BRIC Anti-obesity Drugs Market by Region: Global Market Share 2019 (%)
  • Figure 6.31 BRIC Anti-obesity Drugs Market Forecast 2019-2030: Revenue ($m), AGR (%)
  • Figure 6.32 BRIC Anti-obesity Drugs Market Forecast 2020 and 2030: Revenue ($m), CAGR 2020-2030 (%)
  • Figure 6.33 BRIC Anti-obesity Drugs Market Forecast by Region: Global Market Share (%), 2030
  • Figure 6.34 BRIC Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2020
  • Figure 6.35 BRIC Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2030
  • Figure 6.36 China Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2030
  • Figure 6.37 India Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2030
  • Figure 6.38 Brazil Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2030
  • Figure 6.39 Russia Anti-obesity Drugs Market Forecast: Revenue ($m), AGR (%),2019-2030
  • Figure 7.1 Anti-obesity Clinical Pipeline Segmentation by Phase, 2019
  • Figure 7.2 Anti-obesity Pipeline Segmentation by Mechanism of Action, 2019
  • Figure 9.1 SWOT Analysis of the Global Anti-obesity Drugs Market
  • Figure 9.2 U.S. Bariatric Surgery, 2011-2017
  • Figure 9.3 Trends in percentage of procedures in USA/Canada from 2003, 2008, 2011, 2013
  • Figure 9.4 Trends in percentage of procedures in Europe from 2003, 2008, 2011, 2013
  • Figure 9.5 Trends in percentage of procedures in Latin/South America from 2003, 2008, 2011, 2013
  • Figure 9.6 Trends in percentage of procedures in Asia-Pacific from 2003, 2008, 2011, 2013
  • Figure 9.7 Prevalence and number of people with diabetes (Adults 18+ Years)
  • Figure 9.8 Risk of general diseases associated with obesity
  • Figure 10.1 Global Anti-obesity Drugs Market by Company 2018: Market Share (%)
  • Figure 10.2 Novo Nordisk's 20-year R&D journey in Obesity - Milestones of Saxenda
  • Figure 11.1 Global Anti-obesity Drugs Market by Region: Share (%), 2019

List of Companies and Organisations Mentioned:

  • ADial Pharmaceuticals
  • AEMPS
  • AIFA HAS
  • Akrimax Pharmaceuticals
  • American Medical Association
  • Arena Pharmaceuticals
  • AstraZeneca
  • Biophytis
  • Boehringer Ingelheim
  • Boston Therapeutics
  • Diasome
  • Eisai
  • EMEA
  • Empros Pharma
  • FDA
  • G-BA
  • GenePreDiT
  • GlaxoSmithKline (GSK)
  • Hanmi
  • Ildong Pharmaceuticals
  • Intarcia Therapeutics
  • Ionis Pharmaceuticals
  • Janssen Pharmaceuticals
  • KT&G Life Sciences
  • KVK Tech
  • Kwang Dong
  • Medivation
  • Medlab Clinical
  • Neothetics
  • NGM Biopharmaceuticals
  • NICE SMC
  • Novartis
  • Novo Nordisk
  • OPKO Health
  • Orexigen
  • Rhythm Pharmaceuticals
  • Roche
  • Saniona
  • Shionogi & Co., Ltd
  • Takeda
  • Teva
  • Valeant Pharmaceuticals
  • Virtici
  • Vivus
  • World Health Organization (WHO)
  • Xenetic Biosciences
  • Zafgen
目次
Product Code: PHA0720

Title:
Global Anti-obesity Drugs Market Forecast 2020-2030
Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs.

The global anti-obesity drugs market is estimated to have reached $1.9bn in 2019 and is expected to grow at a CAGR of 32% in the first half of the forecast period. In 2019, the innovator drugs submarket held 75% of the global anti-obesity drugs market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 285-page report you will receive 146 tables and 137 figures - all unavailable elsewhere.

The 285-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Anti-obesity Drugs Market forecast from 2020-2030

Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action:

  • Incretion mimetics/GLP-1 agonists
  • SNDRIs
  • Lipase Inhibitors
  • Serotonin receptor agonists
  • Sympathomimetic-GABA receptor agonists
  • Sympathomimetics

Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Duration of Therapy:

  • Long-term Drugs
  • Short-term Drugs

Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Innovator vs Generic Drugs:

  • Innovator
  • Generic Drugs

Global Anti-obesity Drugs Market analysis and forecast from 2020-2030, by Prescription vs OTC:

  • Prescription Drugs
  • OTC

This report discusses and provides revenue forecasts from 2020-2030 for selected anti-obesity drugs:

  • Saxenda
  • Contrave/Mysimba
  • Belviq
  • Qysmia
  • Xenical
  • Alli

This report provides individual revenue forecasts from 2020-2030 for these regional and national markets:

  • US
  • Japan
  • EU5: Germany, France, Spain, Italy, UK
  • BRIC: Brazil, Russia, China, India
  • RoW

Each national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugs.

Our study discusses the selected leading companies that are the major players in the anti-obesity drugs market:

  • Arena Pharmaceuticals
  • AstraZeneca
  • Carmot Therapeutics
  • CohBar
  • Currax Pharmaceuticals LLC
  • Eisai
  • ERX Pharmaceuticals
  • Gelesis
  • GlaxoSmithKline (GSK)
  • Hanmi Pharmaceutical
  • LNC Therapeutics
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Rhythm Pharmaceuticals, Inc.
  • Roche
  • Saniona
  • Scohia Pharma, Inc.
  • Sinil Pharmaceutical Co., Ltd
  • Takeda
  • Teva
  • Vivus

This report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.

This report gives an overview of pricing and reimbursement in the US and EU.

This report provides a SWOT Analysis of the global anti-obesity drugs market.

Key questions answered by this report:

  • How is the anti-obesity drugs market evolving?
  • What is driving and restraining anti-obesity drugs dynamics?
  • How will each anti-obesity drugs submarket market grow over the forecast period and how much Sales will these submarkets account for in 2030?
  • How will market shares of each anti-obesity drugs submarket develop from 2020-2030? Which individual technologies will prevail and how will these shifts be responded to?
  • Which anti-obesity drugs submarket will be the main driver of the overall market from 2020-2030?
  • How will political and regulatory factors influence regional anti-obesity drugs markets and submarkets?
  • Will leading national anti-obesity drugs markets broadly follow macroeconomic dynamics, or will individual country sectors outperform the rest of the economy?
  • How will market shares of the national markets change by 2030 and which nation will lead the market in 2030?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the sector evolve as alliances form during the period between 2020 and 2030?

Visiongain's study is intended for anyone requiring commercial analyses for the anti-obesity drugs market. You find data, trends and predictions.

Buy our report today Global Anti-obesity Drugs Market Forecast 2020-2030: Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Why You Should Read This Report
  • 1.2 How This Report Delivers
  • 1.3 Key Questions Answered by This Analytical Report:
  • 1.4 Who is This Report for?
  • 1.5 Methodology
    • 1.5.1 Primary Research
    • 1.5.2 Secondary Research
    • 1.5.3 Market Evaluation & Forecasting Methodology
  • 1.6 Frequently Asked Questions
  • 1.7 Associated Reports
  • 1.8 About Visiongain

2. Introduction to Obesity

  • 2.1 What is Obesity?
    • 2.1.1 Types of obesity
      • 2.1.1.1 Central Obesity / Android Type
      • 2.1.1.2 Peripheral Obesity/ Gynoid Type
  • 2.2 What are the causes and risk factors of obesity?
    • 2.2.1 Energy Imbalance
    • 2.2.2 Genetic Predisposition
    • 2.2.3 Unhealthy Diet
    • 2.2.4 Health Conditions and Medicines
    • 2.2.5 Emotional Factors
    • 2.2.6 Age
    • 2.2.7 Pregnancy
    • 2.2.8 Lack of Sleep
    • 2.2.9 Smoking
  • 2.3 Obesity Measurement
    • 2.3.1 BMI
    • 2.3.2 Waist circumference
    • 2.3.3 Index of Central Obesity
    • 2.3.4 Bioelectrical Impedance Analysis
    • 2.3.5 New Approaches/Techniques
  • 2.4 Epidemiology of Obesity
    • 2.4.1 Epidemiology by Geography
    • 2.4.2 Epidemiology by Country
    • 2.4.3 Historical Prevalence in Major Markets
    • 2.4.4 Forecast of Obesity Prevalence in Major Markets
  • 2.5 Humanistic and Economic Burden
    • 2.5.1 Mortality
    • 2.5.2 Morbidity
      • 2.5.2.1 Disability-adjusted life year (DALY)
      • 2.5.2.2 Years Lost due to Disability (YLD)
      • 2.5.2.3 Years of Life Lost (YLL)
    • 2.5.3 Economic Impact
  • 2.6 Obesity: Prevention and Treatment
    • 2.6.1 Lifestyle changes
    • 2.6.2 Pharmacotherapy
    • 2.6.3 Other treatments

3. Introduction to the Global Anti-obesity Drugs Market

  • 3.1 Market Structure
  • 3.2 Market Definition and Scope
  • 3.3 Classification by Mechanism of Action
    • 3.3.1 Incretin Mimetics/GLP-1 Agonists
    • 3.3.2 Lipase Inhibitors
    • 3.3.3 Serotonin-norepinephrine-dopamine Reuptake (SNDRI) Inhibitors
    • 3.3.4 Serotonin Receptor Agonists
    • 3.3.5 Sympathomimetics
    • 3.3.6 Sympathomimetic-GABA Receptor Agonists
    • 3.3.7 Others
  • 3.4 Classification by Innovator or Generics Drugs
    • 3.4.1 Innovator Drugs
    • 3.4.2 Generics Drugs
  • 3.5 Classification by Prescription or OTC drugs
    • 3.5.1 Prescription drugs
    • 3.5.2 OTC drugs
  • 3.6 Classification by Duration of Therapy
    • 3.6.1 Short-term drugs
    • 3.6.2 Long-term drugs

4. Global Anti-obesity Drugs Market 2020-2030

  • 4.1 Global Anti-obesity Drugs Market 2019
  • 4.2 Global Anti-obesity Drugs Market Forecast 2020-2030
  • 4.3 Global Anti-obesity Drugs by Mechanism of Action
    • 4.3.1 Global Anti-obesity Drugs by Mechanism of Action: Market Forecasts 2020-2030
      • 4.3.1.1 Incretin mimetics/GLP-1 Agonists: Market Forecasts 2020-2030
      • 4.3.1.2 Lipase Inhibitors: Market Forecasts 2020-2030
      • 4.3.1.3 Serotonin-norepinephrine-dopamine Reuptake Inhibitors (SNDRI): Market Forecasts 2020-2030
    • 4.3.2 Serotonin Receptor Agonists: Market Forecasts 2020-2030
      • 4.3.2.1 Sympathomimetic-GABA Receptor Agonists: Market Forecasts 2020-2030
      • 4.3.2.2 Sympathomimetics: Market Forecasts 2020-2030
      • 4.3.2.3 Others: Market Forecasts 2020-2030
    • 4.3.3 Global Anti-obesity Drugs Market Forecasts by Mechanism of Action: Market Share 2020-2030
  • 4.4 Global Anti-obesity Drugs Market by Innovator and Generics Drugs
    • 4.4.1 Global Anti-obesity Drugs by Innovator Drugs and Generics: Market Forecasts 2020-2030
      • 4.4.1.1 Innovator Drugs: Market Forecasts 2020-2030
      • 4.4.1.2 Generics: Market Forecasts 2020-2030
    • 4.4.2 Global Anti-obesity Drugs Market Forecast by Innovator Drugs and Generics: Market Share 2020-2030
  • 4.5 Global Anti-obesity Drugs Market by Prescription and OTC Drugs
    • 4.5.1 Global Anti-obesity Drugs Market by Prescription and OTF Drugs: Market Forecast 2020-2030
      • 4.5.1.1 Prescription Drugs: Market Forecasts 2020-2030
      • 4.5.1.2 OTC Drugs: Market Forecasts 2020-2030
    • 4.5.2 Global Anti-obesity Drugs Market Forecast by Prescription and OTC Drugs: Market Share 2020-2030
  • 4.6 Global Anti-obesity Drugs Market by Duration of Therapy
    • 4.6.1 Global Anti-obesity Drugs Market by Duration of Therapy: Market Forecast 2019-2030
      • 4.6.1.1 Short-term Anti-obesity Drugs: Market Forecasts 2020-2030
      • 4.6.1.2 Long-term Anti-obesity Drugs: Market Forecasts 2020-2030
    • 4.6.2 Global Anti-obesity Drugs Market Forecast by Duration of Therapy: Market Share 2019-2030
  • 4.7 Overall Global Anti-obesity Drugs Market Drivers, Restraints and Trends

5. Leading Anti-obesity Drugs

  • 5.1 Snapshot of Anti-obesity Drugs
  • 5.2 Innovator Drugs
    • 5.2.1 Saxenda
      • 5.2.1.1 Saxenda Drug Profile
      • 5.2.1.2 Saxenda Historical Sales
      • 5.2.1.3 Saxenda Forecast 2020-2030
      • 5.2.1.4 Saxenda Sales by Geography, 2018
    • 5.2.2 Contrave / Mysimba
      • 5.2.2.1 Contrave Drug Profile
      • 5.2.2.2 Contrave Historical Sales
      • 5.2.2.3 Contrave Forecast 2020-2030
      • 5.2.2.4 Contrave Sales by Geography, 2018
    • 5.2.3 Belviq
      • 5.2.3.1 Belviq Drug Profile
      • 5.2.3.2 Belviq Historical Sales
      • 5.2.3.3 Belviq Forecast 2020-2030
      • 5.2.3.4 Belviq Sales by Geography, 2018
    • 5.2.4 Qysmia
      • 5.2.4.1 Qysmia Drug Profile
      • 5.2.4.2 Qysmia Historical Sales
      • 5.2.4.3 Qysmia Forecast 2020-2030
      • 5.2.4.4 Qysmia Sales by Geography, 2018
    • 5.2.5 Xenical and Alli
      • 5.2.5.1 Xenical and Alli Historical Sales
      • 5.2.5.2 Xenical and Alli Sales by Geography, 2018
      • 5.2.5.3 Xenical and Alli Forecast 2020-2030
    • 5.2.6 Cametor/Oblean
    • 5.2.7 Lomaira
  • 5.3 Generics
    • 5.3.1 Orlistat
      • 5.3.1.1 Orlistat Historical Sales
    • 5.3.2 Sibutramine
      • 5.3.2.1 Sibutramine Historical Sales
    • 5.3.3 Adipex
      • 5.3.3.1 Adipex Historical Sales
    • 5.3.4 Phentermine
      • 5.3.4.1 Phentermine Historical Sales

6. Leading National Markets Forecast 2020-2030

  • 6.1 Geographical Breakdown of Global Anti-obesity Drugs Market, 2019
    • 6.1.1 Regional Breakdown of Global Anti-obesity Drugs Market, 2019
    • 6.1.2 Country Breakdown of Global Anti-obesity Drugs Market, 2019
  • 6.2 Regional Forecast of Global Anti-obesity Drugs Market, 2019-2030
  • 6.3 US Anti-obesity Drugs Market
    • 6.3.1 US Anti-obesity Drugs: Market Forecasts 2020-2030
  • 6.4 Japan Anti-obesity Drugs Market
    • 6.4.1 Japan Anti-obesity Drugs: Market Forecasts 2020-2030
  • 6.5 EU5 Anti-obesity Drugs Market, 2019
    • 6.5.1 EU5 Anti-obesity Drugs: Market Forecast 2020-2030
      • 6.5.1.1 The UK Anti-obesity Drugs: Market Forecasts 2020-2030
      • 6.5.1.2 Germany Anti-obesity Drugs: Market Forecasts 2020-2030
      • 6.5.1.3 France Anti-obesity Drugs: Market Forecasts 2020-2030
      • 6.5.1.4 Italy Anti-obesity Drugs: Market Forecasts 2020-2030
      • 6.5.1.5 Spain Anti-obesity Drugs: Market Forecasts 2020-2030
  • 6.6 BRIC Anti-obesity Drugs Market, 2019
    • 6.6.1 BRIC Anti-obesity Drugs: Market Forecasts 2020-2030
      • 6.6.1.1 China Anti-obesity Drugs: Market Forecasts 2020-2030
      • 6.6.1.2 India Anti-obesity Drugs: Market Forecasts 2020-2030
      • 6.6.1.3 Brazil Anti-obesity Drugs: Market Forecasts 2020-2030
      • 6.6.1.4 Russia Anti-obesity Drugs: Market Forecasts 2020-2030

7. Research and Development for Treating Obesity

  • 7.1 Novel Mechanism of Action of Pipeline Drugs
  • 7.2 Active Pipeline Molecules
  • 7.3 Promising Potential Pipeline Molecules
    • 7.3.1 Phase III Molecules
      • 7.3.1.1 BTI-320
    • 7.3.2 Phase II Molecules
      • 7.3.2.1 Oxyntolong
      • 7.3.2.2 Antisense FGFR4 oligo, Verva
      • 7.3.2.3 S-237648
      • 7.3.2.4 Setmelanotide
      • 7.3.2.5 Bupropion + zonisamide SR
      • 7.3.2.6 Semaglutide
      • 7.3.2.7 LIK066
      • 7.3.2.8 Tesofensine
      • 7.3.2.9 LIPO-202
      • 7.3.2.10 Canagliflozin and Phentermine
      • 7.3.2.11 OBEP-100
      • 7.3.2.12 Efpeglenatide
      • 7.3.2.13 EMP16
      • 7.3.2.14 MEDI-0382

8. Pricing and Reimbursement Overview

  • 8.1 US
  • 8.2 EU
  • 8.3 Payers Perspective

9. Qualitative Analysis of the Global Anti-obesity Drugs Market

  • 9.1 SWOT Analysis, 2019
  • 9.2 Market Trends in Weight Loss & Management Market

10. Leading Companies in Global Anti-obesity Drugs Market, 2019

  • 10.1 Novo Nordisk
    • 10.1.1 Obesity Care - To Establish its presence
  • 10.2 Currax Pharmaceuticals LLC
    • 10.2.1 Currax™ Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
  • 10.3 Eisai Co., Ltd.
    • 10.3.1 Collaboration Agreement with EUROFARMA
    • 10.3.2 Collaboration Agreement with CY BIOTECH
  • 10.4 F. Hoffmann-La Roche Ltd.
  • 10.5 Vivus
    • 10.5.1 Collaboration Agreement with Alvogen Malta Operations (ROW) Ltd
    • 10.5.2 Collaboration Agreement with Other Companies
  • 10.6 Teva
  • 10.7 GlaxoSmithKline (GSK)
  • 10.8 Pfizer Inc.
  • 10.9 Rhythm Pharmaceuticals, Inc.
  • 10.10 AstraZeneca
  • 10.11 Saniona
  • 10.12 Hanmi Pharmaceutical
  • 10.13 SCOHIA PHARMA, Inc.
  • 10.14 Sinil Pharmaceutical Co., Ltd
  • 10.15 ERX Pharmaceuticals
  • 10.16 CohBar, Inc.
  • 10.17 Carmot Therapeutics, Inc.
  • 10.18 LNC Therapeutics
  • 10.19 Gelesis

11. Conclusions

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.